EydisBio is an emerging pharmaceutical company located in Durham, NC. EydisBio is focused on developing small molecule inhibitors towards difficult to treat diseases. Our primary program has focused on developing selective TAK1 inhibitors for the treatment of autoimmune diseases such as systemic sclerosis and rheumatoid arthritis. Our team of experienced drug developers help guide our program and have demonstrated great success in being the first group to selectively target TAK1 therapeutically in pre-clinical models. Our pioneering studies have shown the therapeutic potential of TAK1 in pre-clinical models and our immediate goal is to advance a lead candidate towards first in human studies.